Implantica publishes Interim Report January - September 2023

 

Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.

The company's Certified Adviser is FNCA Sweden AB, info@fnca.se  

This information is information that Implantica AG is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 2023-11-22 08:00 CET.

About Implantica

Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica's lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further information.

The following files are available for download:

https://mb.cision.com/Main/19732/3880355/2446212.pdf

Implantica Q3 2023_Financial Report ENG

https://mb.cision.com/Public/19732/3880355/ba2e6c1d995f91ea.pdf

Implantica publishes Interim Report Jan - Sep 2023 Q3

 

View original content:https://www.prnewswire.co.uk/news-releases/implantica-publishes-interim-report-january--september-2023-q3-301995664.html